News Releases
Roche Drug Receives New European Union Approval
Roche announced that the European Commission has approved Avastin ( bevacizumab ) in combination with standard chemotherapy ( carboplatin and paclitaxel ) as a front-line (first-line following surgery) treatment for women with advanced ovarian cancer.
Merck Announces Multiple Myeloma Drug Trial Results
Merck announced today that a Phase III study of Zolinza ( vorinostat ), for investigational use in combination with bortezomib in patients with progressive multiple myeloma , met its primary endpoint, demonstrating a 23 percent reduction in the risk of progression compared to the standard therapy of bortezomib (p=0.01).
Erwinaze Approved to Treat Leukemia
The U.S. Food and Drug Administration has approved Erwinaze ( asparaginase Erwinia chrysanthemi ) to treat patients with acute lymphoblastic leukemia (ALL), who have developed an allergy (hypersensitivity) to E. coli derived asparaginase and pegapargase chemotherapy drugs used to treat ALL.
Cervical Cancer Guidelines From American Cancer Society
The American Cancer Society (ACS), the American Society for Colposcopy and Cervical Pathology (ASCCP), and the American Society for Clinical Pathology (ASCP) have proposed new guidelines for the prevention and early detection of cervical cancer.
Late-Stage Melanoma Drug Approved
The U.S. Food and Drug Administration has approved Zelboraf (vemurafenib), a drug to treat patients with late-stage (metastatic) or unresectable (cannot be removed by surgery) melanoma, the most dangerous type of skin cancer.
AstraZeneca announces trade name Caprelsa for vandetanib
AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) has approved the trade name Caprelsa for the recently approved orphan drug vandetanib, a treatment for medullary thyroid cancer that cannot be removed by surgery or that has spread to other parts of the body.
Pfizer and Acura Announce FDA Approval of Oxecta
Pfizer Inc. and Acura Pharmaceuticals Inc. announce the marketing approval from the U.S. Food and Drug Administration (FDA) of OXECTATM (oxycodone HCl, USP) Tablets CII. OXECTA is indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.
Major Prostate Cancer Development
An international, multi-center study has found that a recently FDA-approved drug called abiraterone acetate significantly improves overall survival in men with metastatic prostate cancer by more than 34 percent.
FDA Approves Drug for Advanced Pancreatic Cancer
Basel, May 5, 2011 - Novartis announced today that the US Food and Drug Administration (FDA) approved Afinitor (everolimus) tablets for the treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease.
A Plan to Help the Pre-existing Condition Crowd
The U.S. Department of Health and Human Services (HHS) is increasing awareness about a health plan for uninsured Americans with pre-existing conditions created by the Affordable Care Act.